| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications.
Editor's Note: Fierce life sciences publications, including FierceLifeSci Weekly Digest, won't be in your inbox next week, but we will be covering breaking news on FiercePharma.com and FierceBiotech.com. Our newsletters will be back in the New Year. Happy holidays! | |
|
Featured Story | | | Wednesday, December 20, 2017 Will Shire investors get a Christmas present in the form of a buyout? As Republicans put the final touches on their new tax plan, so too are large pharma companies circling Shire for a potential acquisition, according to The Telegraph. |
|
|
Top Stories Of The Week Wednesday, December 20, 2017 AbbVie has scored another key trial win with its blockbuster-in-waiting JAK1 inhibitor upadacitinib (ABT-494), but a death and pulmonary embolism take some of the shine off the data. Tuesday, December 19, 2017 At a time when drugmakers—even rare disease drugmakers—routinely draw fire for their pricing decisions, Spark Therapeutics is surely prepping a pitch for its now-FDA-approved Luxturna. Analysts figure the pioneering therapy's retail price could break the $1 million barrier. Tuesday, December 19, 2017 Genentech has entered into a multitarget drug discovery deal with DiCE Molecules. The Roche unit is handing over an upfront fee and committing to milestones to apply DiCE’s small molecule platform to targets of interest. Monday, December 18, 2017 Scientists at the military’s Walter Reed Army Institute of Research announced that they’ve developed a heroin vaccine that can block the euphoric effects of opioids in the brain—and do so without interfering with other therapies used to treat addiction. Thursday, December 21, 2017 One of the fastest-growing classes of diabetes drugs now has a new contender: Steglatro, the SGLT2 drug from Merck & Co. and Pfizer. When it rolls out in January, the drug will have to tackle the tough task of winning share from some already entrenched rivals. Wednesday, December 20, 2017 Thanks for the advice, but no thanks. That's what Teva told Israeli officials Tuesday after Prime Minister Benjamin Netanyahu encouraged the debt-laden drugmaker to keep open its manufacturing facility in Jerusalem in the wake of last week’s announcement of stunning cuts worldwide. Wednesday, December 20, 2017 Zimmer Biomet named Bryan Hanson, an executive at rival devicemaker Medtronic, as its new president and chief executive. Wednesday, December 20, 2017 JSR Life Sciences’ parent company will pay NT$12 billion ($400 million) for Crown Bioscience International, boosting its global footprint and CRO offerings. Tuesday, December 19, 2017 As lawmakers in the Philippines question officials involved in the world’s first mass dengue vaccination program, ex-president Benigno Aquino III defended his administration’s decision to launch it. But that's not likely to deter those intent on pushing further investigation. Resources Presented By: Patheon When a biologics company prepares to launch a new product, it must forecast the capacity it will need. Download Patheon's whitepaper to learn how to mitigate risks by developing a manufacturing strategy that will accommodate a forecast range and allow you to adapt as better data becomes available. Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. | 